Health technology startup Temple has acquired Longevous, a London longevity medical practice, as it prepares to launch a wearable and develop the scientific case behind its health measurements. The transaction gives Temple clinical and research leadership, but it does not establish that the company’s wearable or its proposed Entropy metric can measure aging, predict health risk or improve health outcomes.
Evidence at a glance
- Development: Temple acquired Longevous for an undisclosed amount.
- Leadership: Longevous cofounder Dr. Robert Mohr becomes Temple’s chief medical officer, and cofounder Dr. Avi Roy becomes head of science.
- Product stage: Temple is developing wearable health technology and says scientific manuscripts are being prepared.
- Evidence level: Company Development.
- Main caution: Publicly available peer-reviewed evidence has not established that Temple’s Entropy metric is clinically valid or useful.
What the acquisition changes
Longevous will continue operating as part of Temple, according to reporting on the August 27 announcement. Mohr and Roy are joining Temple full time while continuing to work with the clinic’s clients.
Mohr will oversee the clinical rigor of Temple’s experiments and health-related claims as chief medical officer. Roy, an Oxford-trained biomedical scientist, will lead scientific work. Their appointments give the wearable company direct access to clinicians, patients and a team experienced in preventive and longevity-focused medicine.
The purchase price was not disclosed. The significance of the deal is therefore strategic rather than financial: Temple is bringing a medical practice and scientific leadership inside the company while its first consumer product is still being prepared for a wider launch.
What Temple says it is building
Temple describes its product as a wearable intended to track physiological and health signals. The company has discussed cerebral blood flow, metabolic demand and sympathetic nervous-system activity as areas of interest.
The sympathetic nervous system helps regulate the body’s rapid response to stress, including heart rate, blood-vessel tone and energy use. Signals related to this system can be meaningful, but turning them into a reliable measure of long-term health requires validation across different ages, conditions and real-world settings.
Temple also uses the term Entropy for an internally developed measurement that it says reflects the metabolic and sympathetic demand placed on the body. That is the company’s proposed interpretation. It should not yet be confused with a validated medical endpoint.
What is confirmed
The acquisition, leadership appointments and continued operation of Longevous are confirmed elements of the announcement. Temple is developing a wearable, and the Longevous team has reportedly been testing the technology, assessing data and reviewing scientific manuscripts before submission.
That internal work is relevant because it shows the company is attempting to build an evidence program rather than relying only on marketing. It is not independent validation. Researchers employed by or joining a company can conduct rigorous work, but readers still need access to methods, data, predefined analyses and complete results.
What remains unproven
No publicly available peer-reviewed study has yet established that Temple’s Entropy measurement accurately reflects biological aging, future disease risk or a clinically meaningful physiological state. It is also unknown whether the wearable measures its intended signals with sufficient accuracy outside controlled conditions.
A useful health metric must do more than produce a stable number. Researchers need to show what the number represents, how it compares with established measurements, whether it predicts outcomes in new groups and whether changes in the score correspond to meaningful changes in health.
Clinical utility is a still higher bar. Even if a wearable measurement is accurate, users and clinicians need evidence that acting on it leads to better decisions or outcomes. A metric can be scientifically interesting without improving care.
How to evaluate the forthcoming science
When Temple’s manuscripts become public, several details will matter. The studies should clearly describe participant selection, sample size, the signals collected and the algorithm used to produce the Entropy score. Analyses should be tested in data not used to build the model.
Independent replication will be especially important. Wearable algorithms can perform well in a development dataset and then lose accuracy when tested across different skin tones, body types, medications, health conditions or daily routines. Comparisons with accepted clinical measurements should be defined before results are known.
Conflicts of interest should also be disclosed. Company-funded and company-run research is not automatically unreliable, but readers need to know who designed the study, controlled the data and decided what to publish.
Why a clinic may be valuable to a wearable company
A medical practice can provide practical feedback that a technology team may lack. Clinicians can identify measurements that are confusing, difficult to act on or disconnected from patient needs. Longitudinal clinical relationships may also help researchers understand how signals change over time.
At the same time, combining product development with clinical care requires careful boundaries. Patients should understand when a measurement is experimental, what evidence supports it and whether participation in research is optional. Experimental scores should not be presented as diagnoses.
The Lifespan Brief assessment
Temple’s acquisition of Longevous is a meaningful longevity-industry development because it moves clinical and scientific expertise into the company before the wearable’s broader launch. It may improve Temple’s ability to test its ideas and communicate limitations responsibly.
The transaction itself validates no scientific claim. Temple’s credibility will depend on the quality, transparency and independent reproducibility of the evidence it releases. Until those manuscripts and results are available for scrutiny, Entropy and the wearable should be treated as developing company technology, not established medical tools.
Sources
Inc42 reporting on Temple’s acquisition of Longevous, August 27, 2026.